Investor Presentation First Nine Months of 2022
110
Investor presentation First nine months of 2022
International Operations at a glance.
Diabetes trend
Million
Diabetes market by value and Novo
Nordisk market share
Novo Nordisk reported sales
600
400
200
0
M
487
2021
587
2030
Population with diabetes
Diabetes growth rate
DKK
billion
19%
250
17%
First nine months
of 2022
Sales
(mDKK)
Growth²
80%
Total GLP-13
18,886
55%
Long-acting insulin4
8,717
0%
200
35.5%¹
60%
Premix insulin5
7,855
-9%
GLP-1
Fast-acting insulin
8,291
-3%
150
Insulin
Human insulin
4,967
-20%
720
4.5%1
40%
Total insulin
29,830
-7%
100
Other Diabetes care?
1,913
-12%
20%
Diabetes care
50,629
9%
50
7.9%1
OAD
Obesity care
4,141
73%
0
0%
Diabetes & Obesity
54,770
13%
Aug
2045
2017
Aug
2022
care
Rare disease⁹
9,645
4%
GLP-1 MS
-Insulin MS
-OAD MS
Total
64,415
11%
Novo NordiskⓇ
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: Africa, Europe, Middle East and North Africa, South and Central
America, South East Asia and Western Pacific; Source: International Diabetes
Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for 5-year period; Competitor insulin value market
shares, as of Aug 2022: Novo Nordisk 50%, Sanofi 27% and Eli Lilly 14%;
Competitor GLP-1 value market shares, as of Aug 2022: Novo Nordisk
60%, Eli Lilly 37% and AstraZeneca 2%; OAD: Oral anti-diabetic; MS:
Market share; Source: IQVIA MAT, Aug 2022 value figures
2 At Constant exchange rates; 3 Comprises Victoza®, Ozempic®, and RybelsusⓇ;
4 Comprises TresibaⓇ, XultophyⓇ and LevemirⓇ; 5 Comprises RyzodegⓇ and
NovoMix® 6 Comprises FiaspⓇ and NovoRapidⓇ; 7 Comprises Novo NormⓇ and
needles; 8 Obesity care comprises SaxendaⓇ and Wegovy®; 9 Comprises
primarily NovoSeven®, Novo Eight® NovoThirteen®, Refixia®, EsperoctⓇ,
Norditropin, Vagifem® and ActivelleⓇView entire presentation